Vertex Pharmaceuticals, Inc. (VRTX)

NASDAQ: VRTX · IEX Real-Time Price · USD
+5.92 (2.06%)
Aug 8, 2022 4:00 PM EDT - Market closed
Market Cap 75.25B
Revenue (ttm) 8.35B
Net Income (ttm) 3.19B
Shares Out 256.00M
EPS (ttm) 9.93
PE Ratio 29.60
Forward PE 19.23
Dividend n/a
Ex-Dividend Date n/a
Volume 1,679,037
Open 288.65
Previous Close 288.03
Day's Range 288.65 - 296.95
52-Week Range 176.36 - 296.95
Beta 0.45
Analysts Buy
Price Target 303.97 (+3.4%)
Earnings Date Aug 4, 2022

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical tri... [Read more...]

Industry Biotechnology
IPO Date Jul 24, 1991
Employees 3,900
Stock Exchange NASDAQ
Ticker Symbol VRTX
Full Company Profile

Financial Performance

In 2021, VRTX's revenue was $7.57 billion, an increase of 22.06% compared to the previous year's $6.21 billion. Earnings were $2.34 billion, a decrease of -13.63%.

Financial Statements

Analyst Forecast

According to 35 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is 303.97, which is an increase of 3.41% from the latest price.

Price Target
(3.41% upside)
Analyst Consensus: Buy
Stock Forecasts


Bull Call Spread On Vertex Pharmaceuticals Taps Into Stock's Newfound Strength

Vertex Pharmaceuticals is showing is showing green check marks across the board, and today we will look at a bullish option strategy. The post Bull Call Spread On Vertex Pharmaceuticals Taps Into Stock'...

2 Top Biotech Stocks Defying the Bear Market

These drugmakers are flying high right now.

Other symbols: EXEL

Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch

Vertex Pharmaceuticals made a bullish move on earnings amid a confirmed market rally, leading five stocks to watch this week. The post Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch ap...

Stock Market Takes Bullish Jobs Report In Stride; Vertex Pharmaceuticals Finds Support After Earnings

The stock market fell sharply early Friday on news of strong job growth in July, but indexes pared losses by the close. The post Stock Market Takes Bullish Jobs Report In Stride; Vertex Pharmaceuticals ...

Why Vertex Pharmaceuticals Stock Was Soaring Today

The company's popular Trikafta continues to boost the fundamentals.

Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance

Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.

Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 3.45% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharma Easily Beats Quarterly Forecasts And Raises 2022 Outlook

Vertex Pharmaceuticals said its triple-regimen in cystic fibrosis is gaining new users abroad. VRTX stock jumped late Thursday.

Vertex Reports Second Quarter 2022 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Reports Second Quarter 2022 Financial Results

Watch These Leaders With Earnings Due, Buy Zones In Focus

With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones. The post Watch These Leaders With Earnings Due, Buy Zones In Focus appeared first on Inv...

My Top Stock to Buy If We're in a Recession

This stock checks off all the boxes.

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Winning Evergreen Stocks to Buy and Hold for the Next 25 Years

These companies have cornered the right markets and are chasing the right long-term trends.

Other symbols: AAPLSTAA

10 Best Low-Volatility Stocks to Buy Now

The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just month...

Is This Vertex Pharmaceuticals' Biggest News Yet?

Vertex's good news has been multiplying.

Vertex Advances VX-548 in Acute and Neuropathic Pain

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that following the positive Phase 2 results earlier this year and having reached agreement on the design of th...

2 Unstoppable Growth Stocks to Buy and Hold for Decades

These businesses are full of growth potential.

Other symbols: GOOGGOOGL

Final Trades: Foot Locker, Vertex, BlackRock & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: FLBLK

4 Profitable Companies With Solid Financial Conditions

When screening the market for value opportunities, investors may want to consider stocks that represent companies with high profitability and robust financial conditions. The companies below meet these ...


Vertex to Announce Second Quarter 2022 Financial Results on August 4

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The compa...

2 Biotech Stocks You Can Buy and Hold for the Next Decade

These drugmakers can help you get through the bear market.

Other symbols: AMGN

Bear Market Winners: 3 Healthcare Stocks That Have Soared More Than 30% This Year

Have these scorching-hot stocks peaked, or could there still be more gains ahead for investors who buy today?

Other symbols: TMDXVERU

3 Stocks to Buy Now That Are Beating the Market

These stocks are largely immune to the economic uncertainties that are worrying investors.

Other symbols: DGUNH

The Overlooked Difference in June's Inflation Report

Today's reaction to a high CPI print is the opposite of what we saw last month.

Other symbols: IBB

Vertex (VRTX) to Buy ViaCyte to Speed Up VX-880 Program

Vertex (VRTX) will acquire ViaCyte for $320 million in cash.